Harvard Scientific (HVSF)Hot$$- male impotency medicine Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Harvard Scientific (HVSF)Hot$$- male impotency medicine

Public Reply Prvt Reply Mark as Last Read File

Next 10PreviousNext

To: gene martineau who wrote ()	12/11/1996 8:30:00 PM
From: gene martineau	of 3906

Harvard Scientific (OTC:BB:HVSF) is a biopharmaceutical company that develops, markets and distributes products relating to liposomal delivery of Prostaglandin for use in the treatment of male erectile dysfunction and impotency. Harvard Scientific has developed a product (Micro-encapsulated Prostaglandin E1) for organically based impotence that is superior to its competition in a number of important areas. The system's liposomal drug encapsulation technology renders it a fast-acting product with fewer side effects. Additionally, its applicator is one-fifth of the size of other comparable products under development and less invasive than existing therapies which use a needle and syringe delivery system. Industry sources estimate that 40 million men suffer from erectile dysfunction and the world wide market for impotency treatment is reported to be $665 million. Treatments presently range from inflatable surgical implants and vacuum constriction devices to needle and syringe injections. Upon approval from the FDA, the Company's treatment could capture a large portion of this market due to its unique application method and reduced cost. Harvard Scientific has developed a treatment that addresses the personal concerns of the patient. The treatment is painless, non-invasive and can be self-administered allowing for patient privacy. The pharmaceutical (Prostaglandin) used in conjunction with the treatment has a 20 year history of therapeutic usage and has recently been recognized and approved by the FDA as a "safe and effective" treatment for erectile dysfunction. In addition, the Company has made strong forward progress in obtaining strategic partners who will market the product world-wide. HVSF expects to have strong world-wide distribution links for its erectile dysfunction product well in advance of product launch. There is significant interest among several well known, and highly qualified, companies. HVSF will be presenting results to the FDA from its ongoing Phase I clinical trials of Prostaglandin E1 in January. In addition HVSF will be presenting a paper concerning its treatment for male erectile dysfunction and impotency at the April, 1997 annual meeting of the American Urological Association (AUA) in New Orleans, LA. The results from the testing performed over the last six months have exceeded the Company's expectations. HVSF will formally request approval from FDA to proceed with the second phase of testing early next year. Phase II and III trials should be able to be completed in 1997. It is anticipated that a pre-market approval application (PMA) will be able to be filed with the FDA in early 1998. This is the final step needed before any sales could begin in the US. HVSF is clearly a turnaround situation, the Company has had upper management problems in the past which are now being resolved. We expect announcements pertaining to this as well as worldwide distribution agreements in the very near future. There are 9.3 million shares of common stock outstanding and approximately 1.5 million in the common float. The Company's common stock traded as high as $16.25 per share in early 1996 on the sole merit of the company's unique delivery system for treatment of male erectile dysfunction. Alternative therapies offered by competitive companies are not as appealing to the end user suffering from this ailment. HVSF last traded at $.93

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Next 10PreviousNext